Collaborative Fund Advisors LLC increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 106.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,142 shares of the pharmaceutical company’s stock after purchasing an additional 1,106 shares during the quarter. Collaborative Fund Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $1,120,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Summit Global Investments acquired a new stake in Vertex Pharmaceuticals during the second quarter valued at approximately $3,568,000. Calamos Advisors LLC grew its position in Vertex Pharmaceuticals by 77.1% in the first quarter. Calamos Advisors LLC now owns 77,886 shares of the pharmaceutical company’s stock valued at $34,779,000 after acquiring an additional 33,917 shares during the period. Danica Pension Livsforsikringsaktieselskab bought a new stake in Vertex Pharmaceuticals in the second quarter valued at $13,823,000. UNIVEST FINANCIAL Corp acquired a new position in Vertex Pharmaceuticals during the second quarter worth $4,495,000. Finally, Meeder Advisory Services Inc. bought a new position in Vertex Pharmaceuticals during the 2nd quarter valued at about $3,187,000. Institutional investors own 90.96% of the company’s stock.
Trending Headlines about Vertex Pharmaceuticals
Here are the key news stories impacting Vertex Pharmaceuticals this week:
- Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up 12% year over year and ahead of estimates, with cystic fibrosis medicines and newer products including CASGEVY and JOURNAVX contributing. The company raised its 2026 revenue outlook, while management highlighted the potential for povetacicept, which faces an FDA decision for IgA nephropathy on November 30. Vertex Q3 2026 earnings call highlights
- Positive Sentiment: Analyst actions have generally been supportive: Barclays raised its price target to $626 and kept an overweight rating, while H.C. Wainwright reiterated Buy and TD Cowen also rated the shares Buy. These endorsements may bolster confidence in Vertex’s growth prospects.
- Neutral Sentiment: Investors are also focused on Vertex’s efforts to expand beyond cystic fibrosis into kidney and rare endocrine diseases—potential future growth drivers, but ones that will take time to establish. Vertex: 3 key takeaways for long-term investors
- Negative Sentiment: Quarterly earnings per share came in below analyst expectations, and acquisition costs weighed on profit. Reports also pointed to lighter-than-hoped-for sales of the pain drug JOURNAVX, contributing to a selloff after the earnings release. Vertex slumps on light pain drug sales
Vertex Pharmaceuticals Price Performance
Vertex Pharmaceuticals stock opened at $549.04 on Thursday. The business’s 50-day simple moving average is $522.90 and its 200 day simple moving average is $480.92. The stock has a market cap of $139.35 billion, a price-to-earnings ratio of 35.33, a P/E/G ratio of 2.56 and a beta of 0.28. Vertex Pharmaceuticals Incorporated has a 12-month low of $406.67 and a 12-month high of $568.67. The company has a quick ratio of 2.74, a current ratio of 2.34 and a debt-to-equity ratio of 0.17.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The business had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same period last year, the firm earned $4.80 earnings per share. The company’s quarterly revenue was up 11.8% on a year-over-year basis. As a group, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 16.64 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research firms have commented on VRTX. JPMorgan Chase & Co. boosted their price target on shares of Vertex Pharmaceuticals from $560.00 to $570.00 and gave the company an “overweight” rating in a research report on Tuesday. Evercore lifted their target price on shares of Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an “outperform” rating in a research note on Wednesday, September 2nd. Canaccord Genuity Group increased their price target on Vertex Pharmaceuticals from $436.00 to $442.00 and gave the stock a “hold” rating in a research report on Tuesday, August 4th. Truist Financial lifted their price objective on Vertex Pharmaceuticals from $560.00 to $565.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, TD Cowen raised their target price on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the company a “buy” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $596.44.
Check Out Our Latest Stock Analysis on Vertex Pharmaceuticals
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.
Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
